Liquid chromatographic analysis in mouse, dog and human plasma; stability, absorption, metabolism and pharmacokinetics of the anti-HIV agent 2-chloro-5-(2-methyl-5,6-dihydro-1,4-oxathiin-3-yl carboxamido) isopropylbenzoate (NSC 615985, UC84)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 17, Issue 1, 1998, Pages 27-38

  Nomeir, Amin A ^a,c   McComish, Madeline F ^a   Ferrala, Nicolas F ^a   Denise Silveira, ^a   Covey, Joseph M ^b   Chadwick, Marjory ^a  

^a Arthur D Little Inc   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Absorption; Anti HIV agent; Metabolism; NNRTI; NSC 615985; Reversed Phase LC; UC84

Indexed keywords

2 CHLORO 5 (2 METHYL 5,6 DIHYDRO 1,4 OXATHIIN 3 YLCARBOXAMIDO)ISOPROPYLBENZOATE; ACETONITRILE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LIPOSYN II; POTASSIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-HIV AGENTS; CARBOXIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; HUMANS; MALE; MICE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0032080488     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(97)00159-3     Document Type: Article

References (14)

1. Weislow O.S., Kiser R., Fine D.L., Bader J., Shoemaker R.H., Boyd M.R. J. Natl. Cancer Inst. 81:1989;577-586.
2. J.P. Bader, J.B. McMahon, R.J. Schultz, V.L. Narayanan, J.B. Pierce, W.A. Harrison, O.S. Weislow, C.F. Midelfort, S.F. Stinson, M.R. Boyd, Proc. Natl. Acad. Sci. USA 88 (1991) 6740-6744.
3. Schultz R.J., Narayanan V.L., Pierce J., Harison W.A., Bader J.P., Boyd M.R. Proc. Am. Assoc. Cancer Res. 31:1990;2425.
4. Balzarini J., Jonckheere H., Harrison W.A., Dao D.C., Anné J., De Clercq E., Karlsoon A. Antiviral Chem. Chemother. 6:1995;169-178.
5. Balzarini J., Pérez-Pérez M.J., Vélazquez S., San-Félix A., Camarasa M.-J., De Clercq E., Karlsoon A. Proc. Natl. Acad. Sci. USA. 92:1995;5470-5474.
6. P.G. Welling, Pharmacokinetics: Process and Mathematics (ACS monograph 185), American Chemical Society, 1986, pp. 213-240.
7. Karnes H.T., Shiu G., Shah P.V. Pharm. Res. 8:1991;421-426.
8. Nomeir A.A., McComish M.F., Mongan A.L., Covey J.M., Ferrala N.F. J. Pharmaceut. Biomed. Anal. 12:1994;693-698.
9. Leinweber F.J. Drug Metab. Rev. 18:1987;379-439.
10. Mitchell S.C., Waring R.H. Drug Metab. Rev. 16:1986;255-284.
11. Hajjar N.P., Hodgson E. Science. 209:1980;1134-1136.
12. Ziegler D.M. Drug Metabol. Rev. 19:1988;1-31.
13. Waring R.H. Xenobiotica. 3:1973;65-71.
14. Stinson S.F., Schultz R.J., Malspeis L. Proc. Am. Assoc. Cancer Res. 36:1995;2173.